drugset / Trial / NCT02171585
Bioavailability of Dabigatran With or Without Clarithromycin in Healthy Volunteers
Non-randomizedCrossoverOpen-labelTreatment
Summary
To investigate whether and to what extent the reported potent P-gp inhibitor clarithromycin affects pharmacokinetic parameters (area under the curve (AUC) and maximal concentration (Cmax)) of dabigatran.
Timeline
- Start
- 2008-06
- Primary completion
- 2008-08
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dabigatran etexilate | Unknown | 150 mg | Oral |
| Background | Clarithromycin | Small molecule | 500 mg | Oral |
Indications
No indication recorded.